APA (7th ed.) Citation

RL, G., AJ, N., SK, M., A, B., AK, B., CY, C., . . . ID, R. (2024). Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): Extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. The Lancet. Respiratory medicine, 12(12), 975. https://doi.org/10.1016/S2213-2600(24)00186-3

Chicago Style (17th ed.) Citation

RL, Goodall, et al. "Long-term Efficacy and Safety of Two Short Standardised Regimens for the Treatment of Rifampicin-resistant Tuberculosis (STREAM Stage 2): Extended Follow-up of an Open-label, Multicentre, Randomised, Non-inferiority Trial." The Lancet. Respiratory Medicine 12, no. 12 (2024): 975. https://doi.org/10.1016/S2213-2600(24)00186-3.

MLA (9th ed.) Citation

RL, Goodall, et al. "Long-term Efficacy and Safety of Two Short Standardised Regimens for the Treatment of Rifampicin-resistant Tuberculosis (STREAM Stage 2): Extended Follow-up of an Open-label, Multicentre, Randomised, Non-inferiority Trial." The Lancet. Respiratory Medicine, vol. 12, no. 12, 2024, p. 975, https://doi.org/10.1016/S2213-2600(24)00186-3.